Author(s):
Gopala Krishna Devisetty, Mahammad Ishaq Beludari
Email(s):
drbmdishaq@gmail.com
DOI:
10.52711/0974-360X.2026.00230 
Address:
Gopala Krishna Devisetty1, Mahammad Ishaq Beludari*2
1Department of Chemistry, College of Applied Sciences and Pharmacy, University of Technology and Applied Sciences, Muscat, Oman.
2Department of Pharmacy, College of Applied Sciences and Pharmacy, University of Technology and Applied Sciences, Muscat, Oman.
*Corresponding Author
Published In:
Volume - 19,
Issue - 4,
Year - 2026
ABSTRACT:
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and has become a serious public health problem worldwide. There are various antidiabetic drugs on the market, but most of these drugs cause many side effects such as diarrhea, kidney failure, musculoskeletal pain, and enlarged urinary system infections in the clinical treatment of T2DM. Therefore, there is a need for new antidiabetic drugs that can be used orally, are safe with improved efficacy, and reduced side effects. Currently, drugs targeting aldose reductase, peroxisome proliferator-activated receptor gamma (PPAR-?), and alpha-glucosidase (a-glucosidase) play a crucial role in the treatment of T2DM. This study focuses on the synthesis and design of a novel benzoyl hydrazone derivative as a possible inhibitor of elevated aldose reductase, based on rational drug design. Because of their potential for therapeutic use, hydrazone-type Schiff bases have been extensively studied. Among other things, these substances are known to possess antioxidant, antifungal, antibacterial, and anticancer qualities. In this study, derivatives of cinnamaldehyde and 4-Hydroxy benzhydrazide reacted in a methanolic medium to create a hydrazone-based Schiff base. The synthesized compounds were characterized using several spectroscopic methods, including ¹H NMR, FTIR, and high-resolution mass spectrometry. Additionally, they were evaluated in silico on a-glucosidase, PPAR-?, and aldose reductase. Using molecular docking investigations with auto dock, the mechanisms of the enzyme-ligand interactions between the produced hydrazone molecules and target enzymes were investigated here. Furthermore, these drugs' pharmacokinetic appropriateness and ADME characteristics were assessed using Lipinski and Veber's guidelines. The molecule demonstrated strong ADME qualities and the highest binding affinity against PPAR-?, aldose reductase, and a-glucosidase. Additionally, it has been noted that the active hydrazone molecule forms hydrogen bonds with important amino acid residues on target enzymes. By significantly advancing experimental research, these data can direct the creation of novel antidiabetic medications.
Cite this article:
Gopala Krishna Devisetty, Mahammad Ishaq Beludari. Rational Design, Synthesis, and Computational Assessment of Novel Benzoyl Hydrazone Derivatives as Multifunctional Antidiabetic agents Targeting α-Glucosidase, PPAR-γ and Aldose Reductase. Research Journal of Pharmacy and Technology. 2026;19(4):1611-7. doi: 10.52711/0974-360X.2026.00230
Cite(Electronic):
Gopala Krishna Devisetty, Mahammad Ishaq Beludari. Rational Design, Synthesis, and Computational Assessment of Novel Benzoyl Hydrazone Derivatives as Multifunctional Antidiabetic agents Targeting α-Glucosidase, PPAR-γ and Aldose Reductase. Research Journal of Pharmacy and Technology. 2026;19(4):1611-7. doi: 10.52711/0974-360X.2026.00230 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-4-19
REFERENCES:
1. Kalra S, Kumar A. Diabetes as a communicable disease. JPMA. The Journal of the Pakistan Medical Association. 2019; 69(1): 127-129.
2. Ramachandran A. Epidemiology of diabetes in Indians. International Journal of Diabetes in Developing Countries. 1993; 13: 65-67.
3. Bose JP. A Handbook on Diabetes Mellitus and its Modern Treatment. 1928.
4. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, et al. Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015; 1(1): 1-22.
5. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018; 14(2): 88-98.
6. Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators of Inflammation. 2013; 2013: 549627.
7. Stumvoll M. Thiazolidinediones–some recent developments. Expert Opinion on Investigational Drugs. 2003; 12(7): 1179-1187.
8. Flora GD, Nayak MK. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Current Pharmaceutical Design. 2019; 25(38): 4063-4084.
9. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007; 30(10): 2458-2464.
10. Thakur S, Gupta SK, Ali V, Singh P, Verma M. Aldose reductase: a cause and a potential target for the treatment of diabetic complications. Archives of Pharmacal Research. 2021; 44: 655-667.
11. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design. 2005; 11(18): 2279-2299.
12. Dalal SR, Chang EB. Disorders of epithelial transport, metabolism, and digestion in the small intestine. In: Yamada's Textbook of Gastroenterology. 2015: 1276-1293.
13. Leroux-Stewart J, Rabasa-Lhoret R, Chiasson JL. α-Glucosidase inhibitors. In: International Textbook of Diabetes Mellitus. 2015: 673-685.
14. Martin AE, Montgomery PA. Acarbose: An α-glucosidase inhibitor. American Journal of Health-System Pharmacy. 1996; 53(19): 2277-2290.
15. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. American Journal of Health-System Pharmacy. 2006; 63(10): 929-938.
16. Krishna DK, Devanna N, Chandrasekhar KB. A comparative study of cobalt (II) using 4-hydroxy 3,5 dimethoxy benzaldehyde 4-hydroxy benzoyl hydrazone and cinnamaldehyde 4-hydroxy benzoylhydrazone in presence of micellar medium by spectrophotometry. International Journal of Pharma and Bio Sciences. 2011; 2(1): 341-354.
17. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7): 13384-13421.
18. Kubinyi H. Combinatorial and computational approaches in structure-based drug design. Current Opinion in Drug Discovery and Development. 1998; 1(1): 16-27.
19. Ivanova L, Karelson M. The impact of software used and the type of target protein on molecular docking accuracy. Molecules. 2022; 27(24): 9041.
20. Ghorban DL, Madadkar SA, Shafiei A, Mahmoudian M. Flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm. 2004: 1-10.
21. Bakchi B, Krishna AD, Sreecharan E, Ganesh VBJ, Niharika M, Maharshi S, Puttagunta SB, Sigalapalli DK, Bhandare RR, Shaik AB. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: a medicinal chemist's perspective. Journal of Molecular Structure. 2022; 1259: 132712.
22. Quezada-Calvillo R, Nichols B. Digestion and Absorption of Carbohydrates. Adequate Food for All. 2009;69-87.
23. Godavari A, Amutha K. In vitro Antidiabetic Activity of Garcinia mangostana by Enzymatic Inhibition Assay. Research J. Pharm. and Tech. 2017; 10(2): 508-512.
24. Anjitha R, Umamaheswari Subbaraya, Gopinathan Narasimhan. Integrated Invitro-Insilico screening strategy of Ethanolic extract of leaves of Passiflora edulis Sims var. flavicarpa against Alpha Glucosidase. Research J. Pharm. and Tech. 2020; 13(3): 1309-1313.
25. Arwa R. Althaher. In vitro Assessment of the Antidiabetic Activity of Aqueous and Ethanolic Extracts from the Aerial Parts of Ajuga orientalis L. Research Journal of Pharmacy and Technology. 2023; 16(4): 1828-2.
26. Candra Irawan, Maman Sukiman, Imalia Dwi Putri, Riri Enriyani, Andita Utami, Lintannisa Rahmatia, Wira Aditia Septian. Antioxidant Activity, Alpha-Glucosidase Inhibitors Ethanol Extract of Vernonia amygdalina Del. and Nutraceutical Potential. Research Journal of Pharmacy and Technology. 2024; 17(2): 571-7.
27. Djohan, Bungaran Sihombing, Sahna Ferdinand. Exploring Nanoherbal Tomato: Assessing its Potential as an α-Glucosidase and α-Amylase Inhibitor, Antioxidant and Metabolite Profiling using LC-HRMS. Research Journal of Pharmacy and Technology. 2024; 17(10): 4953-0.
28. T. Sundarrajan, V. Velmurugan, R.Srimathi. Phytochemical Evaluation and In Vitro Antidiabetic Activity of Ethanolic extract of Alternanthera ficodia Linn. Research J. Pharm. and Tech. 2017; 10(9): 2981-2983.
29. Gupta JK. The role of aldose reductase in polyol pathway: An emerging pharmacological target in diabetic complications and associated morbidities. Curr Pharm Biotechnol. 2024; 25(9): 1073-81.
30. R. Sathish Kumar, C. Aarthi. Insilico Prediction of Binding Efficiency for the Phytoconstituents from Traditional Medicinal Plants against Diabetes Target: Aldose Reductase. Research J. Pharm. and Tech. 2017; 10(11): 3709-3712.
31. M.Sumithra, Shatabdi Choudhury, L S Dhivya, M Nithiyanand, Jimson Zachariah, Sharmila. Protective role of Borreria hispida against Galactosamine Induced Diabetic Cataract. Research J. Pharm. and Tech. 2019; 12(3): 1235-1238.
32. Gaviraj EN, Ramarao A, Veeresham C, Shivakumar B, Kalyane NV, Biradar SM. Inhibitory activities of some Folklore remedies on Aldose reductase of rat lens and generation of advanced glycation end products. Research J. Pharm. and Tech. 2019; 12(4): 1947-1952.
33. Ahsan W. The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: a current perspective. Curr Pharm Des. 2019; 25(23): 2540-54.
34. Surendra Nath Pandeya, Rajeev Kumar, Arun Kumar, Ashish Kumar Pathak. Antidiabetics Review on Natural Products. Research J. Pharm. and Tech. 2010; 3(2): 300-318.
35. S. Adhikary, C.C. Kandar, P.K. Haldar, A. Basu, S. Choudhury. Preclinical Evaluation of Antidiabetic Effect of Pedilanthus tithymaloides Extracts in Streptozotocin (STZ) Induced Diabetic Rats. Research J. Pharm. and Tech. 2010; 3 (4): 1132-1133.
36. Harinarayan Singh Chandel, A K Pathak, Mukul Tailang. Characterization of Some Herbal Antidiabetic Drugs in Polyherbal Formulation by Microscopy. Research J. Pharm. and Tech. 2011; 4 (1): 131-145.
37. Chauhan H.V. In-Vivo Antidiabetic, Lipid Lowering and Antioxidant Activities of Methanolic Extaract of Lawsonia inermis Leaves. Research J. Pharm. and Tech. 2011; 4(5): 764-767.
38. Vasudev Pai, Rudraprabhu V. Savadi, Anant Bhandarkar. In-Vitro Alpha-Amylase Inhibition Action of Isolated Phytoconstituent in Zanthoxylum rhetsa (Roxb) Bark. Research J. Pharm. and Tech. 2011; 4(7): 1147-1150.
39. M. Ponnanikajamideen, S. Rajeshkumar, G. Annadurai. In Vivo Antidiabetic and In Vitro Antioxidant and Antimicrobial Activity of Aqueous Leaves Extract of Chamaecostus cuspidatus. Research J. Pharm. and Tech. 2016; 9(8): 1204-1210.
40. Yogesh Vaishnav, Arvind Kumar Jha, Shekhar Verma, Pranita Kashyap, Chanchal Deep Kaur. A Review on Antidiabetic Activity of Substituted 1, 3, 4 –Thiadiazole Derivatives. Research J. Pharm. and Tech. 2017; 10(12): 4467-4470.